[{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"1c1d3f40-f2af-499a-b04e-123bc4d694d0","acronym":"ON-TRK","url":"https://clinicaltrials.gov/study/NCT04142437","created_at":"2021-01-18T20:13:13.808Z","updated_at":"2025-02-25T15:26:13.445Z","phase":"","brief_title":"Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body","source_id_and_acronym":"NCT04142437 - ON-TRK","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/03/2020","start_date":" 04/03/2020","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-02-10"},{"id":"f0aa223d-45fe-469e-a692-cb8949633296","acronym":"NAVIGATE","url":"https://clinicaltrials.gov/study/NCT02576431","created_at":"2021-01-17T17:25:20.190Z","updated_at":"2025-02-25T15:42:38.245Z","phase":"Phase 2","brief_title":"A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors","source_id_and_acronym":"NCT02576431 - NAVIGATE","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 07/20/2025","primary_completion_date":" 07/20/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-10"},{"id":"277136d1-0119-42be-9629-e04f1cfca67d","acronym":"TRIDENT-1","url":"https://clinicaltrials.gov/study/NCT03093116","created_at":"2021-01-17T17:11:31.349Z","updated_at":"2025-02-25T16:31:09.380Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","source_id_and_acronym":"NCT03093116 - TRIDENT-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-07"},{"id":"402908a9-d0e1-4f21-92f5-1af6168ee4aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06141005","created_at":"2025-02-26T07:39:11.997Z","updated_at":"2025-02-26T07:39:11.997Z","phase":"","brief_title":"Feasibility of Bronchial Washing Fluid for Molecular Testing with Next Generation Sequencing in Lung Cancer","source_id_and_acronym":"NCT06141005","lead_sponsor":"Pusan National University Hospital","biomarkers":" EGFR • HER-2 • ALK • RET • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • RET mutation • ROS1 fusion","tags":["EGFR • HER-2 • ALK • RET • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • RET mutation • ROS1 fusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 08/29/2024","primary_completion_date":" 08/29/2024","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2025-01-03"},{"id":"245c1786-d5c4-49a7-8439-75f183f39949","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783323","created_at":"2023-03-24T16:04:14.237Z","updated_at":"2025-02-25T17:26:04.484Z","phase":"Phase 2","brief_title":"Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer","source_id_and_acronym":"NCT05783323","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 02/14/2024","start_date":" 02/14/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-11-12"},{"id":"c992b4e8-e799-41ef-b989-1921ae3a3287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556228","created_at":"2021-01-18T17:30:17.557Z","updated_at":"2024-07-02T16:34:59.667Z","phase":"Phase 1","brief_title":"Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03556228","lead_sponsor":"VM Oncology, LLC","biomarkers":" NTRK1","pipe":" | ","alterations":" NTRK1 fusion • NTRK1 mutation • NTRK expression","tags":["NTRK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK1 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMD-928"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 06/08/2018","start_date":" 06/08/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-31"},{"id":"130047ee-0a8b-4a61-991a-4693497b26dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04879121","created_at":"2021-05-10T14:53:10.353Z","updated_at":"2024-07-02T16:35:05.353Z","phase":"Phase 2","brief_title":"Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04879121","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":"","alterations":" ","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 11/11/2025","primary_completion_date":" 11/11/2025","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2024-05-07"},{"id":"41b01b41-ccaf-44d0-9901-ee4360f0dfd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828303","created_at":"2023-04-25T14:03:37.911Z","updated_at":"2024-07-02T16:35:10.118Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05828303","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-04-11"},{"id":"1cdd60d2-369d-4e42-890d-606bbb974c28","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010342","created_at":"2023-08-24T16:11:42.524Z","updated_at":"2024-07-02T16:35:10.443Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","source_id_and_acronym":"NCT06010342","lead_sponsor":"Teligene US","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TL118"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-10"},{"id":"dcc86dfa-5f1f-487e-97bd-3b553b98917f","acronym":"STARTRK-NG","url":"https://clinicaltrials.gov/study/NCT02650401","created_at":"2021-01-18T12:54:05.938Z","updated_at":"2024-07-02T16:35:12.285Z","phase":"Phase 1/2","brief_title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","source_id_and_acronym":"NCT02650401 - STARTRK-NG","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-29"},{"id":"8214fea8-a403-48c1-9fa6-030636cc99e1","acronym":"STARTRK-2","url":"https://clinicaltrials.gov/study/NCT02568267","created_at":"2021-01-17T17:20:53.382Z","updated_at":"2024-07-02T16:35:12.401Z","phase":"Phase 2","brief_title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","source_id_and_acronym":"NCT02568267 - STARTRK-2","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 534","initiation":"Initiation: 11/19/2015","start_date":" 11/19/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-28"},{"id":"9eaee900-c56a-440b-bf3e-d9e5c14d97d5","acronym":"ADVL1823","url":"https://clinicaltrials.gov/study/NCT03834961","created_at":"2021-01-18T18:56:06.238Z","updated_at":"2024-07-02T16:35:13.156Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia","source_id_and_acronym":"NCT03834961 - ADVL1823","lead_sponsor":"Children's Oncology Group","biomarkers":" NTRK1 • NTRK3 • NTRK2 • ETV6","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2 • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/25/2019","start_date":" 10/25/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-22"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"78482e2a-4e36-4c51-a81b-de4897029fc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05004116","created_at":"2021-08-13T12:53:24.897Z","updated_at":"2024-07-02T16:35:15.181Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer","source_id_and_acronym":"NCT05004116","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-03-12"},{"id":"96e82999-ebea-468e-ae05-e9929f4ac0ba","acronym":"DARANIVOVAX","url":"https://clinicaltrials.gov/study/NCT06015724","created_at":"2023-08-29T16:10:12.521Z","updated_at":"2025-02-25T14:18:13.340Z","phase":"Phase 2","brief_title":"Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06015724 - DARANIVOVAX","lead_sponsor":"Georgetown University","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • STK11","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 mutation • KRAS G12","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-02-05"},{"id":"ad35a256-b12d-4264-8406-c8f148399527","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828277","created_at":"2023-04-25T14:03:37.480Z","updated_at":"2024-07-02T16:35:35.756Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients","source_id_and_acronym":"NCT05828277","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2 • AFP • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2 • AFP • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2022","start_date":" 07/28/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-26"},{"id":"b9d29ac1-22f0-48b2-a031-d017175875c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05914116","created_at":"2023-06-22T19:11:45.274Z","updated_at":"2024-07-02T16:35:37.381Z","phase":"Phase 1/2","brief_title":"A Study of DB-1311 in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05914116","lead_sponsor":"DualityBio Inc.","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT324"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-09-12"},{"id":"d0232ee2-cfb8-4d08-8138-198a58818661","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769075","created_at":"2023-03-15T14:02:16.876Z","updated_at":"2024-07-02T16:35:49.864Z","phase":"Phase 1","brief_title":"A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations","source_id_and_acronym":"NCT05769075","lead_sponsor":"TYK Medicines, Inc","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • ALK rearrangement • ALK fusion • ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • ALK rearrangement • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TY-2136b"],"overall_status":"Recruiting","enrollment":" Enrollment 282","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-04-24"},{"id":"3e913d99-df53-4faa-8b4e-40650b3c220b","acronym":"RNASARC","url":"https://clinicaltrials.gov/study/NCT03375437","created_at":"2021-01-18T16:39:34.592Z","updated_at":"2024-07-02T16:35:51.030Z","phase":"","brief_title":"RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.","source_id_and_acronym":"NCT03375437 - RNASARC","lead_sponsor":"Centre Leon Berard","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK fusion • ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK fusion • ROS1 fusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 376","initiation":"Initiation: 02/15/2018","start_date":" 02/15/2018","primary_txt":" Primary completion: 02/15/2024","primary_completion_date":" 02/15/2024","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-04-10"},{"id":"c81fb89a-a657-47dd-9b13-7d83c2b9a7e0","acronym":"APT-CUBE","url":"https://clinicaltrials.gov/study/NCT05473156","created_at":"2022-07-25T20:54:40.231Z","updated_at":"2024-07-02T16:35:56.496Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","source_id_and_acronym":"NCT05473156 - APT-CUBE","lead_sponsor":"AP Biosciences Inc.","biomarkers":" BRAF • MET • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation","tags":["BRAF • MET • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AP203"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-02-03"},{"id":"ea4a5d4d-7485-48e5-9caf-f1b9a939013f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04444427","created_at":"2021-01-18T21:23:07.457Z","updated_at":"2024-07-02T16:35:58.581Z","phase":"Phase 1b/2","brief_title":"Evaluation of GLR2007 for Advanced Solid Tumors","source_id_and_acronym":"NCT04444427","lead_sponsor":"Gan and Lee Pharmaceuticals, USA","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK1 • NTRK","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1 • NTRK1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLR2007"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 07/15/2020","start_date":" 07/15/2020","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 07/29/2022","study_completion_date":" 07/29/2022","last_update_posted":"2022-12-23"},{"id":"1e22027b-b2bf-474b-a73a-9d16197e47de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05348668","created_at":"2022-04-27T13:53:49.092Z","updated_at":"2024-07-02T16:36:11.362Z","phase":"Phase 2","brief_title":"Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05348668","lead_sponsor":"Anhui Provincial Hospital","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" BRAF V600E • KRAS G12C • BRAF V600 • MET exon 14 mutation • KRAS G12","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS G12C • BRAF V600 • MET exon 14 mutation • KRAS G12"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2022-04-27"}]